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1 
INTRODUCTION 
Pemphigus is a chronic autoimmune blistering disorder of the skin and 
mucosa. The word pemphigus, is derived from the greek word “pemphix” meaning 
a bubble or blister. It is characterized by the development of flaccid intra-epidermal 
bullae, erosions and ulcerations over the skin and/ or mucosa with antibodies 
directed against desmogleins 1 and 3.
1
 Demonstration of immune deposits has been 
the gold standard for diagnosis of Pemphigus, more specifically the Direct immune 
fluorescence of peri-lesional skin or mucosa demonstrating intercellular deposition 
of IgG and/or C3.  
The disease usually begins with only oral lesions and may eventually 
progress to involve the skin.
2
 Early diagnosis of the condition helps in controlling 
the disease activity and involvement of other areas with the help of early initiation 
of treatment. 
Systemic steroids alone or in combination with other immuno-supressants 
are the mainstay of treatment which has significant adverse effects and hence a 
proper confirmatory test is required before starting treatment. At present the 
recommended technique is by DIF of oral mucosa. 
Recently, Pemphigus specific immunofluorescence pattern has been 
demonstrated in the outer root sheath of hair follicles which is structurally similar to 
the epidermal keratinocytes with a sensitivity of 85-100%.
3-6 
2 
Hence, DIF of hair could be taken up as an ideal substrate for the diagnosis 
of Pemphigus as it is a simple, non-invasive and a cost effective procedure instead 
of DIF of mucosa which is an invasive and expensive procedure with lesser patient 
compliance. 
 
 
 
 
 
 
 
 
 
 
 
  
 
3 
AIM 
• Comparison of Direct Immunofluorescence of Oral mucosa and plucked Hair 
in patients with Oral Pemphigus. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
4 
NEED FOR THE STUDY 
The current technique implemented as a gold standard for diagnosis of oral 
Pemphigus is DIF of the oral mucosa which is a painful procedure for the patient 
and difficult to carry out for the clinician as well. 
Hence by this study we would like to suggest an easier, less invasive and 
cheaper method of using plucked hair from the scalp as a substrate for DIF to prove 
Oral Pemphigus.  
 
 
 
 
 
 
 
 
 
  
5 
REVIEW OF LITERATURE 
History 
The term pemphigus was first used in the period 460-370 B.C by 
Hippocrates.  He enumerated different types of fevers and mentioned a pemphigoid 
type of fever.
7 
 
Pemphigus was first described in the year 1777 by McBride and Wichmann 
in 1791. Wichmann applied the term “pemphigus” to patients who had flaccid 
bullae and painful oral ulcers.
7 
 
In 1844 - Cazenave first described pemphigus foliaceous as a superficial, 
rapidly spreading form of pemphigus 
8 
 
In 1868, Ferdinand von Hebra stated that pemphigus was a chronic disease 
and was the first to coin the term pemphigus vulgaris.
7-8 
 
In 1886, Neumann described a disease with “warty granulations” as 
pemphigus vegetans.
9 
 
In 1881- disruption of epidermal cells in patients with pemphigus, was first 
described by Auspitz.
10 
 
6 
In 1925, Senear and Usher described pemphigus erythematosus
8
. In 1943, 
Civatte delineated acantholysis as histo-pathologic hallmark in pemphigus. He 
described acantholysis and intraepithelial bulla formation in pemphigus vulgaris, 
pemphigus foliaceous and pemphigus vegetans. These findings distinguished 
pemphigus from other blistering disorder of the skin.
11 
 
In 1953, Walter Levers distinguished pemphigus vulgaris and pemphigoid 
bullosus, by both clinical and histological parameters. He described pemphigus 
vulgaris as a life-threatening disease, characterized by intra-epidermal blisters and 
acantholysis with usually a lethal outcome.
12 
 
In 1964, Beutner and Jordon demonstrated auto-antibodies on the cell 
surface of keratinocytes by direct immunofluorescence.
13 
 
In 1976- Schiltz and Michel, by human skin organ culture demonstrated that 
auto-antibodies in pemphigus cause the blister formation
14 
 
In 1982, Anhalt et al demonstrated the auto-antibodies in pemphigus by 
means of passive transfer of antibodies to neonatal mice.
15 
 
In 1980s, pemphigus target antigens were identified by immune-precipitation 
and immune-blotting methods.
16 
 
7 
In the early 1990s, isolation of cDNA for pemphigus antigens revealed
 
the 
desmogleins as the target antigens in pemphigus.
17 
 
EPIDEMIOLOGY 
Worldwide: 
Pemphigus Vulgaris prevalence ranges from 0.18 to 6.96 case per million 
population all over the world.
18    
In the United Kingdom the incidence was 0.58 to 0.80 per 100,000 person 
years.
19 
In France, the prevalence was 1.7 cases per million population per year.
20 
In Tunisia, the prevalence was 6.7 cases per million population per year.
20 
In Iran, the mean incidence was 0.67 cases per million population per year.
21 
India: 
A survey conducted in Kerala showed 4.4 per million population incidence 
of pemphigus vulgaris per year. This was higher than United Kingdom, France, 
Germany & Iran but lesser than Tunisia.
22 
Among the dermatology outpatients in India, the incidence varies from 0.09 
to 1.8%.
23
   
8 
  Among pemphigus patients, the majority are diagnosed to have pemphigus 
vulgaris, the proportion being as high as 75- 92% 
22 
followed by pemphigus 
foliaceous, pemphigus erythematosus and pemphigus vegetans in decreasing order 
of  frequency.
24 
Gender: 
In general, both sexes are equally affected though various studies have 
shown contrasting results.
22 
Age: 
In India, majority of the patients have been younger than 40 years of age. 
This is in contrast to other parts of the world where pemphigus occurs in the 5
th
 and 
6
th
 decade of life.
25 
Race: 
More prevalent among Jewish and Mediterranean population.
22 
Genetic Factors: 
Pemphigus is a polygenic disorder, i.e the disease depends on the 
simultaneous presence of several genes. Higher incidence of Pemphigus vulgaris 
and earlier age at onset for pemphigus seen in Indian population have been 
attributed to higher frequency of DSG3*TCCCC in Indian population.
22 
9 
HLA DRB1 *0402, 1401/04, HLA DQB1 * 0503 has been associated with 
increased susceptibility to PV, HLA DRB1 *04 associated with P.F (both sporadic 
and endemic form) and HLA DRB1 *0102, 0404 & 1402/06 associated with 
endemic P.F.
26-27 
An inherited predisposition is further proved by the following observations: 
a. Difference in clinical profile of Pemphigus among various ethnic groups. 
b. Ashkenazi Jews are more commonly affected. 
c. Familial cases have been reported.  
d. 40-60% of 1st degree relatives of patients with P.V have shown circulating 
anti- desmoglein antibodies.  
e. The first-degree relatives of patients with pemphigus have an increase 
prevalence of auto-immune diseases. 
DISEASE ASSOCIATIONS 
A number of diseases have been described in association with pemphigus 
and these include cryoglobulinemia and cold agglutinin disease,
29
 renal cell 
carcinoma, 
30
 hyperprolactinemia, 
31
 brain abscesses,
32  
SLE, Myasthenia gravis, 
thymoma and lymphoproliferative diseases.
33 
EB virus, Herpes simplex, HHV 6 & 8 have been demonstrated in the skin of 
patients with Pemphigus.
34-35
 Patients with pemphigus having co existing HIV 
infection have also been reported.
36 
10 
Pathogenesis 
The cornerstone of pemphigus is the presence of  IgG auto-antibodies which 
act against desmoglein 3 and/or desmoglein 1. 
These antibodies play an important role in loss of cell to cell adhesion of 
keratinocytes which  further results in blister formation. 
Desmosomes: 
Desmosomes are the major adhesion complex in the epidermis, anchoring 
keratin intermediate filaments to the cell membrane  and bridging adjacent 
keratinocytes and allowing cells to withstand trauma. 
They are also seen in myocardium , meninges and cortex of lymph nodes. 
The main components of desmosomes in the epidermis, consist of products of 
three gene super-families-  
1. the desmosomal cadherins (desmogleins & desmocollins)  
2. the armadillo proteins (plakoglobin, plakophilin)  
3. plakins (desmoplakin, etc) 
Among these desmogleins and desmocollins are the major components.
37 
 
11 
Cadherins are a family of calcium dependent cell-cell adhesion molecules 
that play an important role in formation and maintainence of complex tissue 
integrity.
38 
They have two major subgroups – 
1. classic cadherins 
2. desmosomal cadherins. 
The desmosome has desmosomal cadherins as its transmembrane 
components and plakoglobin, plakophilin and desmoplakin as its cytoplasmic 
components.  
All the cadherins contain repeated amino acid sequences, called cadherin 
repeats, which have calcium-binding motifs in their extracellulardomains. Like the 
classic cadherins, desmogleins have four cadherin repeats in their extracellular 
domain, but with an extra carboxy-terminal domain with repeats of 29 ± 1 
aminoacid residues in their intracellular domain.
38
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Fig 1: Molecular components of desmosomes 
DISTRIBUTION OF DESMOGLEINS IN THE SKIN 
Desmogleins have four isoforms- Dsg 1 to 4 . Desmoglein 1 and 3 is 
basically restricted to the stratified squamous epithelia while Desmoglein 2 is 
expressed in all desmoglein possessing tissues like simple epithelia and 
myocardium. Desmoglein 4 is seen primarily in the hair follicles and in the granular 
layer.
38 
The presence of desmogleins in the skin depends on the differentiation and 
also the pattern of expression in mucosa differs from that in the skin. Desmoglein-3 
expression is restricted to the basal and suprabasal layers of the epidermis, whereas 
13 
desmoglein-1 is present in the entire thickness of the epidermis but more in the 
differentiated cells, i.e, in the upper layers.
39,40
 
Pemphigus IgG antibody binds to the extracellular domain on the amino-
terminal region of dsg-3 and here it has a direct effect on the function of the 
desmogleins.
41 
The pathogenicity of Desmoglein antibodies depends on their titre and 
subclass. 
Patients in whom the disease is active, both IgG1 and IgG4 subclass 
antibodies are present, but the IgG4 is more specific and pathogeneic.
42 
The pathogenicity of desmoglein antibodies is supported by, 
a) Studies showing a correlation between titre of antibody in patient‟s serum 
and the disease activity.
43
 
b) Transient bullae in the newborn may be caused by Transplacental transfer of 
maternal PV antibodies. 
c) PV IgG antibodies causes suprabasal acantholysis in neonatal mouse 
model.
44 
d) Prior absorption of antibodies of the pemphigus vulgaris prevents blister 
formation.
45 
e) Desmoglein-3 antibodies can induce acantholysis can in mice which can be 
enhanced by adding desmoglein-1 antibodies.
46
     
 
14 
Distribution of Desmogleins in Oral Mucosa 
The oral mucosa, which has a characteristic compact lamellar stratum 
corneum, desmoglein 3 is expressed throughout the epithelium. It is also seen that 
the expression of desmoglein 1 is much lower than that of desmoglein 3. 
DISTRIBUTION OF DESMOGLEINS IN THE HAIR  
Desmoglein 1 
It is expressed in the differentiating cells. The distribution is similar to that 
found in the epidermis on the inner root sheath and in the infundibulum of the hair 
follicle. At the level of the bulge it is confined to the suprabasal layers and is absent 
in the basal layer. Desmoglein 1 distribution gradually becomes confined to the 
inner most layers of ORS towards the base. This eventually disappears in the lower 
most part of the hair follicle ORS.
48 
Desmoglein 2 
It is abundantly expressed in the cells with least differentiation such as the 
basal layers of the bulge region of hair follicle and bulb matrix. In the lower part of 
the hair follicle, it is present in the basal cells of the ORS.
48 
Desmoglein 3 
Desmoglein 3 is present on all layer of the ORS, more so in the basal layers. 
At the level of infundibulum it is expressed predominantly in the basal layers. It is 
15 
also expressed in the cyst walls in the areas of trichilemmal keratinisation, medulla 
of the hair shaft, in the suprabasal matrix and the precortical cells.
48 
 Desmoglein 3 
also acts in anchoring the telogen hair to the ORS of the hair follicle.
49 
Desmoglein 4  
Dsg 4 is present in the Inner root sheath, pre-cortex and the matrix.
50 
 
Fig 2: Distribution of desmoglein 1 & 3 in the hair follicle 
 
16 
Table 1
: 
Summary of Dsg expression in hair follicle
39 
Region Dsg 1 Dsg 2 Dsg 3 
Basal cells of infundibulum +/- + ++ 
Suprabasal cells of infundibulum +++ - + 
Isthmus- Suprabasal cells of ORS ++++ + to - +++ to - 
Suprabasal cells of ORS from 
suprabulbar region to bulge 
-To ++ ++ to - +++ to ++ 
Bulge region - +++ + 
Basal cells of ORS below the 
bulge region 
- ++ to +++ +/- 
Precortical cells - + + 
Medulla + - +++ 
Inner root sheath +++ - - 
Matrix - ++ +/- 
 
  
17 
Desmoglein Compensation Theory 
Desmoglein 1 and Desmoglein 3 compensate their adhesive function when 
expressed together on the same cell. The characteristic blisters‟ distribution and 
localization in PV and PF patients can be accounted for by the distribution and 
levels of expression of Desmoglein 1 and 3
51 
The anti-desmoglein autoantibody profile defines the clinical phenotype of 
pemphigus.
52
 Patients with PV have either anti-Dsg3 IgG or have both anti-Dsg3 
and anti-Dsg1 IgG. Patients with Pemphigus Foliaceous have only anti-Dsg1 IgG. 
On the basis of the above findings, the level of blister formation in pemphigus can 
very well be explained. In fact, Pemphigus Foliaceous anti-Dsg1 IgG causes blisters 
in the superficial layers of the epidermis but not in the deep epidermis or mucosa, 
where the expression of Dsg3 compensates for the antibody-induced functional loss 
of Dsg1.  
Similarly, in Mucosal PV, anti-Dsg3 IgG causes acantholysis in the deepest layers 
of the mucous membranes where Dsg1 expression is minimal but not in the skin 
where epidermal integrity is guaranteed by the high expressivity of Dsg1.
53
 Hence 
only oral erosions are seen without apparent skin involvement in mucosal dominant 
Pemphigus Vulgaris. Moreover, in Mucocutaneous PV, both anti-Dsg1 and 
antiDsg3 antibodies are present, hence in the epidermis „low acantholysis‟ occurs as 
well . 
18 
 It is not clear why the split occurs just above the basal layer instead of the whole 
epithelium falling apart. However it is speculated that the cell–cell adhesion 
between the basal and the immediate suprabasal layers might be weaker than the 
other parts of the epidermis, because there are fewer desmosomes. In addition, the 
lower part of the epidermis might have better access for auto-antibodies which 
penetrate from the dermis. That may explain why the splits become suprabasilar in 
Muco-cutaneous PV.
54
 
 
Fig 3: Desmoglein compensation theory 
19 
The coloured triangles represent the distribution of desmoglein (Dsg 1) and 
desmoglein 3(Dsg 3) in the skin and mucous membrane. Sera containing only anti –
Dsg 3 IgG causes no or only limited blisters in the skin because Dsg 1 compensates 
for the loss of Dsg 3 mediated adhesion (A 2) ; however, these sera induce 
separation in the mucous membranes, where the low expression of Dsg 1 will not 
compensate for the loss of Dsg3 mediated adhesion (B2). When sera contains both 
anti Dsg 1 and anti Dsg3 IgG, the function of both Dsgs is compromised and 
blisters occur in both the skin and mucous membranes (A 3 and B 3) 
In spite of acantholysis being well accepted as the basic patho-mechanism in 
Pemphigus, the exact mechanism that causes disruption of the adhesion between 
keratinocytes occurs to be not fully understood. The possible mechanisms are as 
follows: 
1. Steric Hindrance 
Auto antibodies bind to their specific antigens  which in-turn  disrupt 
adhesion of the bound antigens by means of steric hindrance.
55
 PV-IgG 
interfering directly with homophilic Dsg3 transinteraction can be 
demonstrated by means of atomic force microscopy. Neither PV-IgG nor PF-
IgG directly interacts with the homophilic Dsg1. The  Dsg1 transinteraction 
is reduced indirectly via cellular mechanisms.
56 
 
 
20 
2. Basal Cell Shrinkage Theory: 
It appears that PV IgG-induced phosphorylation of adhesion molecules and 
structural proteins leads to weakening of intercellular junctions and collapse 
of the cytoskeleton, respectively. This in turn results in reorganization of the 
keratinocyte cytoskeleton, and hence cellular shrinkage and separation of 
keratinocytes.  
Numerous classical and modern clinical and experimental studies in 
Pemphigus demonstrated that desmosomes separate when the intercellular 
spaces are already widened. Desmosomes do not split and disappear until 
late in acantholysis when keratinocytes are almost completely separated from 
each other. Hence, disruption of intercellular bridges results from ripping 
intact desmosomes off the plasma membrane of collapsing keratinocytes by 
shearing forces. The intact desmosomes ripped off from neighbouring cells 
present in the intercellular space give rise to scavenging autoantibodies.
57
 
3. Apoptolysis Hypothesis 
The apoptolysis hypothesis links the basal cell shrinkage to suprabasal 
acantholysis and cell death, and emphasizes that apoptotic enzymes 
contribute to acantholysis in terms of both molecular events and chronologic 
sequence. Binding of pathogenic auto-antibodies to keratinocytes via a 
receptor –ligand interaction leads to activation of signalling elements and 
21 
elevation of intracellular Ca
2+
, which in turn, initiate cell death enzymatic 
cascades/ caspases. Suprabasal acantholysis starts when basal cells shrink 
due to re-organization of cortical actin filaments, collapse and retraction of 
tonofilaments cleaved by executioner caspases. Acantholysis advances due 
to continued degradation and massive collapse of structural proteins, thus 
separating the collapsing cells and stimulating production of secondary 
antibodies.
58
 Although the pool of anti-keratinocyte antibodies thus produced 
contains anti-Dsg1 and /or Dsg3 antibodies, studies indicate that non-Dsg 
antibodies are the major contributors to early signalling events.
56
 
4. Multiple Hit Hypothesis 
Involvement of multiple autoantibody specificities in Pemphigus 
pathogenesis is explained through the „multiple hit‟ hypothesis. Antibodies 
against keratinocytes acetylcholine receptors – AchR trigger acantholysis by 
weakening the cohesion between neighbouring keratinocytes leading to the 
affected keratinocytes to shrink, causing Desmosomes to be sloughed in the 
intercellular space. These sloughed Desmosomes present in the intercellular 
space stimulate a reciprocal production of scavenger antibodies that in turn 
saturate epidermis thus preventing nascent desmosome formation by steric 
hindrance. Severity of the disease and exact clinical picture depends on the 
ratio of different kinds of auto-antibodies in each particular patient.
59 
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5. Role of T cells 
The role of T- lymphocytes in the pathogenesis of PV is not clear, but auto-
reactive T-cell responses to Dsg-3 may be critical in its pathogenesis.
60
 T-
cell responses to Dsg3 have been detected in PV patients and in healthy 
donors carrying major HLA class 2 alleles identical or similar to those highly 
prevalent in PV. These auto-reactive CD4+ T cells preferentially produce 
Th2 cytokines such as IL-4 and IL-10. Further, auto-antibodies of the Th2-
dependent IgG4 subclass are preferentially seen in active PV, while Th1-
dependent IgG1 auto-antibodies are predominant during remission. Dsg3-
specific, auto-reactive T-cells may thus provide the targets to eventually 
modulate the T-cell dependent production of pathogenic auto-antibodies in 
PV and PF. 
A disturbance in the regulatory mechanisms of Dsg3-specific T cells that 
leads to loss of tolerance at the B-cell level leading to the production of auto-
antibodies has also been demonstrated.
61 
Non Desmoglein Antibodies 
Pemphigus vulgaris sera may also contain auto-antibodies to desmocollins.
62-
63
 Antibodies to cadherin have also been detected, some but not all of which 
crossreact with desmoglein-1.
64 
23 
Antibodies to non-cadherin antigens have also been reported. 
Antidesmoplakin in addition to antidesmoglein antibodies have been reported in 
severe pemphigus vulgaris .
65 
Antibodies to cholinergic receptors have been observed in pemphigus sera
66
 
and cholinergic agonists can inhibit acantholysis induced by Pemphigus sera in 
vitro and have an apparent steroid-sparing effect in vivo in pemphigus.
66
 The 
relative contribution and significance of all the various antibodies described in 
pemphigus remain to be elucidated .
66-67 
DRUG INDUCED PEMPHIGUS 
The causes of drug induced Pemphigus can be divided into 2 groups on the 
basis of the chemical structure. 
1. Thiol/ SH group- penicillamine, captopril, piroxicam, etc 
2. Non thiol group- penicillin, ampicillin, amoxicillin, rifampicin, propanolol, 
phenytoin, phenobarbitone. 
Among these penicillamine is the most commonest cause. Upto 7% Patients 
treated with it for more than 6 months acquire Pemphigus. 
Thiol group of drugs often induced Pemphigus, whereas the non thiol drugs 
trigger the disease in a predisposed individual.
68 
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CLASSIFICATION OF PEMPHIGUS 
1. Pemphigus vulgaris 
2. Pemphigus Vegetans 
3. Pemphigus Foliaceous 
4. Pemphigus Erythematosus 
5. Pemphigus Herpetiformis 
6. Induced pemphigus 
7. Intercellular IgA dermatosis 
8. Paraneoplastic Pemphigus 
CLINICAL FEATURES 
Pemphigus vulgaris can be further classified into 2 types: 
1.) Mucosal type- Dominant mucosal lesions with minimal skin lesions. 
2.) Muco-cutaneous type- i.e mucosal involvement along with extensive bulla 
and erosions in skin. 
MUCOSAL MANIFESTASTION 
The occurrence of oral lesions in Pemphigus vulgaris is seen in all patients 
and a majority of them present initially with them. Cutaneous lesions may develop 
only months later or sometimes oral lesions may be the only manifestation.
69
 Intact 
bullae are rarely seen in the oral cavity. Usually patients have ill-defined, irregularly 
shaped buccal or palatal erosions, which take time to heal. There is peripheral 
25 
extension of the erosions with shedding epithelial shedding.
70
 The conjunctiva, 
nasal, pharynx , larynx, oesophagus , urethra, vulva and cervix are the other 
mucosal surfaces that may be involved.  
CUTANEOUS INVOLVEMENT 
Most patients develop cutaneous lesions. Involvement may rarely remain 
localized to one site 
71
 but more commonly becomes widespread. The disease has a 
predilection for the scalp, face, axilla, groins and pressure points. It usually presents 
as blisters which are flaccid in nature containing clear fluid on normal skin or an 
erythematous base. The contents then become turbid or the blisters rupture, 
resulting in  painful erosions which  tend to extend at the edges as there is more loss 
of epidermis. 
Healing occurs without scarring but pigmentary change and acanthomas may 
occur in resolving lesions .
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Lesions in skin folds readily form vegetating granulations, and flexural 
pemphigus vulgaris merges with its variant Pemphigus vegetans. 
Nail dystrophies, acute paronychia and subungual haematomas have been 
observed in Pemphigus.
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Complications 
The most commonly encountered complication in Pemphigus vulgaris is 
secondary infection, which if not treated could lead to sepsis and then death.  
26 
Complications are also seen as a result of long term treatment with immune-
supressants and steroids. These include hypertension, adrenal axis suppression, fluid 
retention, osteoporosis, diabetes mellitus, cataracts, glaucoma, increased 
susceptibility to infections and reactivation of tuberculosis. 
 
DIFFERENTIAL DIAGNOSIS 
Patients with mucosal lesions present to dental surgeons, oral surgeons and 
gynaecologists. Erosions may simulate acute herpetic stomatitis, erythema 
multiforme, aphthous ulcers or bullous lichen planus. Bullae are transient in the 
mouth and biopsies of erosions may not be diagnostic. 
The diagnosis is less difficult when the patients have cutaneous blisters or 
erosions.  
Blisters in pemphigoid are tense and may be haemorrhagic. The diagnosis of 
pemphigoid is confirmed histologically by showing subepidermal bullae with 
immunoreactants in the basement membrane zone. 
Acute erythema multiforme is a short-lived disorder that may blister, but is 
easily differentiated from pemphigus histologically. 
Blistering in dermatitis herpetiformis is subepidermal and direct 
immunofluorescence of involved and uninvolved skin shows a granular deposition 
of IgA in the basement membrane zone. 
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The histological differential includes Darier‟s disease, Hailey–Hailey disease 
(benign familial chronic pemphigus) and transient acantholytic dermatosis 
(Grover‟s disease). These conditions have distinctive clinical features in addition to 
negative immunofluorescence studies. 
Eosinophilic spongiosis may be an early histological manifestation of either 
pemphigus or bullous pemphigoid.
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Course and prognosis 
During the past few decades, survival of patients with Pemphigus has been 
continually improving. Prior to the advent of corticosteroids, Pemphigus was 
usually fatal. The average mortality rate used to be 29% and since 1970s, the rate 
has fallen to 5%. This has been attributed to the use of immunosupressive agents, 
timely initiation of therapy and improved treatment of complications of steroid 
therapy. The most common causes of death are septicaemia and pulmonary 
embolism. 
The various prognostic factors that have been identified for Pemphigus are:
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1.) The type of Pemphigus:  
Patients with PV and Paraneoplastic pemphigus have the worst prognosis. 
2.) Age of the patient at disease onset:  
Elderly patients have poorer prognosis.
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3.) Disease progression before beginning therapy: 
Patients with minimal disease activity for prolonged periods have a better 
prognosis than patients with rapidly worsening disease. 
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4.) Dose of steroids required to control the disease: 
 Patients who require a daily dose of  >180mg/day of prednisolone, have a 
higher risk of mortality.
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5.) Initial involvement of mucosa or skin: 
 Patients who initially have only cutaneous lesions have a better prognosis 
than those with mucosal involvement.
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6.) Time of institution of therapy: 
 Better prognosis is seen in patients in whom systemic steroid therapy was 
started within 6 months of appearance of disease.
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PEMPHIGUS VEGETANS 
This is a variant of Pemphigus vulgaris that is characterized by vegetating 
erosions affecting predominantly the flexures. 
Two subtypes are recognized:      Neumann Pemphigus vegetans  
Hallopeau pemphigus vegetans. 
In Pemphigus vegetans, tumid, vegetating papillomatous and hypertrophic 
plaques are formed in the intertriginous areas and the flexural surfaces . 
Local moisture, heat and friction are important factors in their development. 
Characteristic glossal changes termed “cerebriform tongue” may be seen.80 
Exuberant vegetating granulations may occur in the oral cavity as well.
81
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SCORING SYSTEMS IN PEMPHIGUS 
As Pemphigus can present with a wide variety of symptoms, it is of 
importance to devise certain objective parameters for evaluation of the disease 
progression or its response to therapy. As a result various scoring systems have 
been used such as , Pemphigus Area and Activity Score, Pemphigus Activity score, 
Pemphigus Disease Activity Index (PDAI), Autoimmune Bullous Skin Disorder 
Intensity Score(ABSIS) etc.
82 
Among these, the scoring systems commonly used are the PDAI score and 
ABSIS score. The PDAI scoring method combines mucosal and cutaneous disease 
and also helps to assess the size and number of lesions with scoring for post 
inflammatory hyperpigmentation as well.
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The advantage of the ABSIS score over the rest is that it is a quality and 
quantity based score for cutaneous lesions and oral mucosa. It also monitors the 
clinical status of the patients over time. 
Signs in Pemphigus 
1. Nikolsky’s sign: 
The sign is positive when a firm tangential pressure with a finger over a bony 
prominence will produce an erosion by separate normal looking epidermis 
from the dermis. 
A positive Nikolsky sign indicates severe disease activity. 
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2. Bulla Spread sign: 
The sign is considered positive when unidirectional pressure applied by a      
finger causes peripheral extension of the bulla beyond the marked margin.
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3. Asboe Hansen sign: 
Pressure is applied to the center of the bulla, which causes peripheral 
extension beyond the marked margins. 
INVESTIGATIONS 
1. Tzanck Smear 
It is the most useful bed side test for Pemphigus. The intact roof of a blister 
is opened on one side and the floor is gently scraped with a glass slide or 
blunt edge of a scalpel. The material obtained is smeared onto a glass slide, 
allowed to air dry and then stained with giemsa stain. 
The smear shows multiple acantholytic cells or tzanck cells. It is a large 
round keratinocyte, with a large nuclear: cytoplasmic ratio and a rim of 
eosinophilic cytoplasm. The staining is deeper and more basophilic 
peripherally on the cell membrane (“mourning edged” cells) due to 
cytoplasm‟s tendency to get condensed at the periphery leading to a peri-
nuclear halo.
84 
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In PF the acantholytic cell is smaller, less rounded, or cuboidal shaped      with 
a small nucleus and abundant cytoplasm. The cells may have keratohyaline 
granules and show keratinization. 
2. SKIN BIOPSY AND HISTOPATHOLOGY 
Biopsy for H&E staining should be preferably taken from an early intact 
bulla or vesicle. In the absence of intact vesicle or bulla, biopsy can be done 
from the edge of an erosion.
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The earliest change in PV is eosinophilic spongiosis or just spongiosis of the 
lower epidermis, which is considered the earliest manifestation of 
acantholysis.
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Acantholysis leads first to the formation of clefts and then to blisters in a 
predominantly suprabasal location. The intraepithelial acantholysis may 
extend into the adnexal structures or occasionally be higher in the stratum 
spinosum. The basal keratinocytes, although separated from one another 
through the loss of attachment remain firmly attached to the dermis like a 
“row of tombstones.” Within the blister cavity, the acantholytic 
keratinocytes, singularly or in clusters, have rounded condensed cytoplasm 
about an enlarged nucleus with peripherally palisaded chromatin and 
enlarged nucleoli.
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There is usually little inflammation but if present it is sparse lymphocytic 
perivascular infiltrate accompanied by dermal edema. 
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In the late stage of the bulla several changes occur. There is mixed inflammatory 
infiltrate of neutrophils, lymphocytes, eosinophils and macrophages in the dermis.
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The bulla ruptures to form an erosion or an ulceration with the base showing 
acantholytic cells. 
An older bulla may show several layers of epidermis at the base as a result of 
keratinocyte migration and proliferation. Lastly, there may be down growth of the 
epidermis giving rise to villi.
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In case of an oral mucosal biopsy it is difficult to demonstrate an intact 
bulla. Hence, only erosions and ulcerations of the mucosa is detected. 
Biopsy is taken from the edge of the erosion with intact adjacent mucosa in order to 
demonstrate the typical pathological findings.
85
 
 
Fig4 :Histopathology of Pemphigus Vulgaris 
 
“row of tomb stone” appearance 
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Pemphigus Vegetans 
Histopathology shows a suprabasal cleft similar to PV but the picture is 
dominated by papillomatosis and acanthosis having pseudo-epitheliomatous picture 
with occasional formation of intra-epidermal eosinophilic abscesses. Villi formation 
and downward proliferation of epithelial strands are more marked. The papillary 
and reticular dermal infiltrate is composed predominantly of eosinophils.  
3. Immunofluorescence 
Immunofluorescence is a laboratory staining technique used to demonstrate 
antibodies or antigens in the tissue or blood or other body fluids. It is a 
technique essential to supplement clinical and histo-pathological findings in 
the diagnosis of immunobullous disorders. 
They play an important role in early diagnosis, treatment and subsequent 
monitoring of disease activity in patients having these disorders. 
Both direct and indirect immunofluorescence can be utilized for the 
diagnosis of pemphigus. The gold standard in the diagnosis of pemphigus is 
considered to be the detection of direct immunofluorescence of skin or mucosa for 
the detection of antidesmoglein 3 and / or 1 antibodies. 
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History 
In 1941, Coons et al first developed the immunofluorescence technique with 
a blue fluorescing compound, β-anthracene, which made it possible to visualize the 
microscopic antigens, antibodies and other elements in tissue sections or cell 
smears.
86   
 
In 1963, diagnostic immunopathology in dermatology began with the 
demonstration of complement and immunoglobulin deposition in the dermo-
epidermal junction of skin - Lupus band test in SLE.
87 
 
Beutner and Jordon demonstrated in the year 1964 the antibodies in the sera 
of Pemphigus patients by indirect immunofluorescence.
88  
 
 
In 1971, Jordon et al. demonstrated the deposition of IgG antibodies at the 
inter-cellular spaces in the epidermis by direct immunofluorescence of the lesional 
and peri-lesional skin.
89 
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Principle Of Fluorescence 
Fluorescence is defined as the light emitted by the singlet state of a molecule on 
returning to its ground state, following absorption of photon from an external 
source. 
 
 
Fig 5: Principle of Fluorescence 
A) Electron in its ground state in a molecule. 
B) Electron excited by a high energy light- UV light and attains a higher energy 
state. 
C) Electron unable to maintain its high energy state and drops to its lowest 
singlet energy state by losing energy as heat. 
D) The electron then spontaneously returns to its original ground state by 
emitting the remaining energy as light with longer wavelength and lesser 
energy in the form of fluorescence 
          A                                 B                                      C                                   D 
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BASIS OF IMMUNOFLUORESCENCE 
In this procedure, the antibodies, antigens or complexes of both are stained 
with corresponding antibodies tagged with a fluorochrome and then viewed under a 
fluorescent microscope with a mercury vapour or xenon light source and 
appropriate exciter and barrier filters.
90
 
Fluorochromes are defined as substances which have the ability to absorb 
light of a particular wavelength and reach an unstable higher energy state. 
Following which, on spontaneously returning to their original state, light with a 
longer wavelength is re-emitted.
91 
 
The commonly used flurochromes are
92 
 Fluorescein isothiocyanate (FITC) 
 Tetramethylrhodamine isothiocyanate (TRITC) 
 Phycoerythrin 
 
FITC produces an apple green fluorescence, while TRITC and phycoerythrin 
produce red fluorescence. 
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TYPES OF IMMUNOFLUORESCENCE 
1. Direct Immunofluorescence 
2. Indirect Immunofluorescence 
3. Complement Indirect Immunofluorescence 
 
Direct Immunofluorescence 
This is a single step method, where the antibody specific to the target 
molecule is tagged with a fluorescent dye. 
In Immuno-bullous disorders FITC tagged tagged anti-immunoglobulin 
antibodies are used for the detection of in-vivo antibodies which are bound to the 
target antigen. 
A specimen for direct immunofluorescence needs to be transported to the 
laboratory in cold normal saline either immediately or if placed in an ice box, 
within few hours of biopsy.  The specimen can also be transported in michels 
medium where it can be stored for upto one month at 4 -8ºC.
93,94 
 
 
 
 
 
38 
Indirect Immunofluorescence 
 
This is a 2 step procedure where the circulating antibodies in the patient‟s 
serum are detected. 
In this technique the antibody specific to the target molecule- the primary 
antibody is unlabeled, and a second anti-immunoglobulin antibody called the 
secondary antibody is directed towards the constant portion of the first antibody-
which is tagged with the fluorescent dye.
93,94 
In autoimmune blistering disorders, first the substrate is incubated with the 
patient‟s serum and then the FITC tagged anti-immunoglobulin antibodies are 
added to it for detection of the pathogenic antibodies.
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Complement Indirect Immunofluorescence 
This is a 3 step IIF technique in which the patient‟s serum is incubated with 
the substrate, then complement is added. 
  Presence of complement in the tissue is then detected by adding fluorescein 
labelled anti-complement antibodies. This test is done to detect complement fixing 
antibodies.
95
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ROLE OF DIRECT IMMUNOFLUORESCENCE IN PEMPHIGUS 
Direct immunofluorescence is considered to be the gold standard in the 
diagnosis of pemphigus with a sensitivity of 95-100%.
95,96  
DIF shows deposition of 
IgG and/ or C3 against desmoglein 3 and / or 1 in the epidermal intercellular spaces. 
This is described as „lace-like‟ or „chicken-wire‟ or „fishnet‟ pattern. In late lesions 
when the acantholytic cells are well developed the classical „fish-net‟ pattern of 
immunofluorescence may become dot-like, corresponding to the aggregation of 
desmosomes on the cell surface.
96 
 
 
Fig - 6: DIF of Pemphigus Vulgaris 
  
“chicken-wire” or “Fish net “ 
pattern 
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The DIF staining shows IgG antibodies in 100 % of positive cases and C3 in 
50-100%.
95
 IgA and IgM may be present, but less frequently. 
Patients with active P.V have both IgG1 and IgG4 subclasses of antibodies 
but the IgG4 is pathogenic.
42 
The intensity of DIF staining correlates with the disease activity. 
However, in few patients it may be positive even when the patient is in 
clinical remission.
95 
In pemphigus vulgaris patients, negative DIF may be an indicator of 
immunological remission. And repeated negative DIF during clinical remission may 
be considered as a possible sign for apparent cure of the disease, and treatment may 
be discontinued in such group of patients.
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False positive DIF 
It is very rare, but non-specific intercellular staining can be seen in psoriasis, 
spongiotic dermatitis, bullous impetigo, and epidermis adjacent to ulcers secondary 
to any cause may have squamous intercellular substance IgG as the intercellular 
space may contain serum.
96 
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DIRECT IMMUNOFLUORESCENCE OF HAIR 
The scalp is a commonly involved site in Pemphigus. Wilson et al, 
demonstrated that, in the scalp, the outer root sheath hair follicle and the dermal 
bulb matrix cells is rich in the target antigens of pemphigus. This may be the reason 
for scalp involvement in Pemphigus.
98 
Recently, it has been shown that outer root sheath of hair follicle which is 
structurally analogous to the epidermal keratinocytes also shows positive direct 
immunofluorescence findings with a sensitivity of 85-100%.
3-6 
Schaerer and Trueb in the year 2003, for the first time, demonstrated 
pemphigus specific DIF pattern in the ORS of the hair follicle of the plucked hair. 
They demonstrated positive DIF findings in 100% of their patients.
3 
Similarly another study demonstrated acantholysis in the hair follicle and 
also immune deposits specific to Pemphigus in the outer root sheath and matrix of 
hair follicle in the biopsy specimens.
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INDIRECT IMMUNOFLUORESCENCE IN PEMPHIGUS 
In this method circulating IgG antibodies are demonstrated in 80-90% of 
pemphigus cases.
96
 The substrates commonly used for IIF include guinea pig 
oesophagus, monkey oesophagus and normal human skin. Of which money 
oesophagus is considered as the ideal substrate.
96 
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IIF has been widely used for monitoring of the serological activity of 
pemphigus patients. It has been demonstrated that the antibody titres in the patients 
sera in many instances, correlates with the disease severity.
99,100 
However, other studies analyzing the serial titres by IIF, showed that the 
antibody titres do not always correlate with disease severity and hence, cannot be 
used as a guide to prognosis or monitoring the disease activity.
101.102 
Judd and Lever found that administration of a high dose of daily steroids 
resulted in clinical improvement as well as showed a marked fall in the titre of 
circulating antibodies. However, there was no predictable correlation between the 
disease activity and antibody titre by IIF when the patients were not receiving a 
high dose of steroids.
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False positive IIF 
False positive immunofluorescence staining can be seen in burns, penicillin 
allergy, toxic epidermal necrolysis, bullous pemphigoid, myasthenia gravis, SLE, 
lichen planus, cicatricial pemphigoid and in patients with antibodies against blood 
group A and B.
133 
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ADVANTAGES OF IMMUNOFLUORESCENCE 
1.) Various auto immune disorders with similar clinical picture are 
classified using immunofluorescence. 
2.) Confirmation of diagnosis in cases where the clinical picture is atypical or 
non specific. 
3.) Circulating antibody level detected by IIF can be used as a prognostic marker 
and also as a marker of disease activity and response to treatment in patients 
diagnosed with pemphigus. 
4.) Antigen mapping can be done, which play an important role in classification 
of various form of hereditary epidermolysis bullosa. 
 
DISADVANTAGES OF IMMUNOFLUORESCENCE 
 
1.) Expensive procedure and requires a lab with cryostat for frozen 
sections and a deep freezer for the storage of these specimens, with a 
well trained technician and a pathologist proficient in the performance 
and interpretation of the results of immunofluorescence. 
2.) DIF stained slides cannot be stored for long-term, as the fluorescent 
stained slides quenches rapidly on exposure to sun light. 
3.) False positive DIF and IIF can occur. 
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LIMITATIONS OF IMMUNOFLUORESCENCE TECHNIQUES 
1. Photobleaching 
It refers to the photochemical reaction which causes reactive oxygen species 
mediated destruction of a fluorochrome in the specimen. It can be reduced by 
decreasing intensity and duration of excitation light, using a low concentration of a 
fluorochrome and addition of singlet oxygen scavengers. 
2. Autofluorescence 
It is due to flavin coenzymes and reduced pyridine nucleotides. Fixation with 
aldehydes, particularly glutaraldehyde, can increase autofluorescence. 
3. Fluorescence Overlap 
The emission signals may sometimes over lap if more than one colour fluorescence 
is emitted. 
Enzyme-Linked Immunosorbent Assay 
Utilizing the recombinant ectodomains of Dsg1 and Dsg3 highly sensitive and 
specific enzyme linked immunosorbent assay (ELISA) have been developed to 
detect the titres of Dsg3 and Dsg1 antibodies in serum. These assays are highly 
sensitive and specific for PV. Anti-desmogleins ELISA assay has shown that 95% 
of PV patients have desmoglein-3 antibodies and around 50% have desmoglein-1 
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antibodies. ELISA titers correlate well with disease activity and are useful to in 
following up the patient.
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OTHER INVESTIGATIONS 
Other than the diagnostic investigations in Pemphigus, investigations such as 
complete blood count, urine routine, Liver function test, Renal function test, fasting 
& post prandial blood sugar, chest x-ray, mantoux test should be done as baseline 
prior to starting the treatment. 
 
TREATMENT OF PEMPHIGUS 
Pemphigus vulgaris if left untreated can be a fatal disease with mortality as 
high as 73% before the advent of corticosteroids.
104 
At present, the first-line treatment of pemphigus is considered to be systemic 
corticosteroids with or without adjuvant immunosuppressive agents. 
The end goal of treatment is maintenance of remission with the least dosage 
of steroids or other immunosuppressives, in order to limit adverse effects of 
treatment. 
Before initiating specific treatment measures, it is important to assess the 
general condition and extent and severity of the disease.  
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Particular attention should be paid to assessing nutrition status, electrolyte 
imbalance and presence of secondary infection. 
Supportive care options required are: 
1. Nursing care: Periodic cleaning and dressing of erosions without extensive 
desloughing until re-epithelisation. This can be done by dressings with sterile 
petrolatum/ antibiotic gauze. Measures should be adapted for prevention of 
bed sores. And finally maintenance of proper oral hygiene. 
2. Nutrition: Soft, protein rich and high calorie diet should be provided as 
there may be loss of proteins and also as patient may be unable to swallow 
due to severe oral ulcerations. If patient is not able to take oral feeds, patient 
may require a feeding tube or parenteral nutrition. 
 
3. Control of secondary infection: Antibiotics should be given preferably 
following a culture and sensitivity report since infection remains the bugbear 
for treatment and if necessary anti-fungals need to be added. 
4. Correction of fluid and electrolyte imbalances: There is increased loss of 
fluids and electrolytes from the erosions and adequate supplementation by 
intravenous route should be provided. 
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Topical Therapy 
Mild localized relapse cases can sometimes be treated with topical therapy 
alone. This can be achieved with either topical clobetasol
105
 propionate or topical 
tacrolimus.
106 
Topical epidermal growth factor has shown to reduce the healing time of 
skin lesions significantly in Pemphigus patients.
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SYSTEMIC CORTICOSTEROIDS 
Systemic corticosteroids are the mainstay of treatment of Pemphigus. 
Prednisolone is the most widely used and time-tested drug hence it is the preferred 
drug. Deflazacort, dexamethasone and betamethasone has also been used. 
For mild to moderate disease, the starting dose of prednisolone is of 60-
80mg/day and for a severe disease 80-120mg/day. The dose can be incremented if 
there is no clinical improvement in a week by upto 50% until the disease activity is 
controlled.
104
  
Once 80-90% of the lesions have healed, the dose can be tapered by 50% 
every 2 weeks till a dosage is reached to maintain clinical remission which is 
usually alternate day therapy. 
Although corticosteroids may provide rapid resolution of lesions, they alone 
are not effective in a significant number of cases. Relative contraindications to the 
48 
use of steroids, serious side effects due to corticosteroids, or if a reduction of dosage 
is not possible due to disease activity, concomitant immunosupressives or other 
adjuvants are advocated.  
DEXAMETHASONE CYCLOPHOSPHAMIDE PULSE THERAPY 
As the side effects of long term corticosteroids itself could contribute to the 
morbidity and mortality, pulse therapy was introduced. 
Pulse therapy means administering bolus dose of a drug at a 
suprapharmacologic dosage over a short period of time and then withdrawing it 
completely till next dose. 
Dexamethasone and cyclophosphamide pulse therapy for pemphigus was 
first proposed in the year 1982 by Parisch et al.
108 
Advantages are : 
1.) Faster healing of lesions 
2.) Faster control of disease activity in extensive disease 
3.) Reduction in total cumulative dosage of CS. 
4.) Cure with minimal CS induced side effects. 109 
Standard DCP therapy consists of 4 phases: 
108 
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Phase 1 
Dexamethasone 100mg is given intravenously dissolved in 500ml of 5% 
dextrose over 3 hours on 3 consecutive days. Cyclophosphamide 500mg is 
dissolved in the same infusion on the second day. The same cycle is repeated again 
every 28 days until all lesions have completely healed and patient is off daily CS. 
Phase 2 
DCP is continued for another 9 months even though lesions have completely 
healed. 
Phase 3 
Monthly DCPs are stopped and cyclophosphamide 50 mg is continued for 
another 9 months and then stopped. 
Phase 4 
This is the period of observation where the patient is drug & disease free and 
under follow up to look for any recurrences. 
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ADJUVANT IMMUNOSUPRESSANTS 
The two main adjuvants are azathioprine and cyclophosphamide for most of 
the patients. Other adjuvants include Mycophenolate Mofetil, Cyclosporine, 
Dapsone and Methotrexate. 
 
AZATHIOPRINE 
One of the most commonly used adjuvants for Pemphigus. It is given at a 
dose of 1-3 mg/kg/day. Ideally the dosage should be adjusted according to the 
TPMT levels. 
The therapeutic effect of azathioprine is seen usually after 3-5 weeks. In 
terms of mortality and remission, Prednisolone with azathioprine is more effective 
than Prednisolone alone.
110 
 
CYCLOPHOSPHAMIDE 
Cyclophosphamide has been used as an adjuvant to CS and is usually given 
at a dose of 1-3 mg/kg body weight. Monthly IV cyclophosphamide in DCP pulse 
therapy with daily oral. Cyclophosphamide in low doses has been used with 
success.
108,111 
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However, it should be used with caution in women of child bearing age and 
in patients who have not yet completed their family, as it‟s known to cause 
secondary infertility due to amenorrhoea and azospermia, on long-term 
administration.
112 
A study has shown that remission in pemphigus can be maintained with low 
dose of Cyclophosphamide alone.
109 
 
MYCOPHENOLATE MOFETIL 
MMF is usually given at a dose of 2-2.5g/day as a steroid sparing agent. One 
randomized controlled trial found MMF to be a less effective than azathioprine as a 
steroid sparing agent.
113 
 
METHOTREXATE 
It can be considered as an adjuvant, if the more commonly used steroid 
sparing agents cannot be used for the patient. Earlier studies with high dose 
methotrexate showed high mortality rate.
114
 However, a recent study has shown that 
methotrexate can be useful and well tolerated in pemphigus patients with a 
considerable steroid sparing effect.
115 
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CYCLOSPORIN 
Initial there were case reports that cyclosporine was a useful adjuvant with 
considerable steroid-sparing effects in PV.
116-118
 However, a recent trial has found 
that cyclosporine as an adjuvant therapy has no benefit over steroids alone.
119 
 
DAPSONE 
Dapsone at a dose of 100-200mg/ day has been tried as an adjuvant in 
pemphigus.
120 
It has been found to be effective as a steroid sparing agent in few 
studies.
121 
 
RITUXIMAB 
It is a chimeric monoclonal anti CD 20 antibody. Its effect, is mainly on the 
B cells. Two studies, have provided valuable data regarding the safety and efficacy 
of rituximab. A study conducted by Cianchini et al , showed that 86 % of patients 
treated with Rituximab achieved clinical remission and discontinued steroid within 
6 months.
122
 And a study by Reguiai et al with 13 Pemphigus patients treated with 
Rituximab achieved clinical remission within the first 3 months.
123 
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Rituximab can be administered by two different protocol: 
123 
 The lymphoma protocol- 375mg/m2 BSA IV weekly for 4 weeks. 
 The rheumatoid arthritis protocol- 1g IV at an interval of 15 days. 
However, the major concern for rituximab is its adverse effects such as 
neutropenia, increased susceptibility to infections, sepsis, DVT. 
IVIG 
IVIG at a dose of 2g/kg body weight divided over 3 days has been tried, this 
cycle is repeated every 4 weeks.
120
 A study showed that a minimum of 3 cycles of 
IVIG produced beneficial effects in 81% of patients with refractory pemphigus. 
Cost is the major limiting factor. 
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                                 Table 2: Side effects of Corticosteroids 
124       
CATEGORY ADVERSE EFFECTS 
Glucocorticoid effect Hyperglycemia, increased appetite 
and weight gain 
Mineralocorticoid effects Hypertension, congestive heart 
failure, arrhythmias secondary to 
hypokalemia, weight gain 
Cutaneous Steroid induced acne, rosacea, 
increased susceptibility to cutaneous 
infections, delayed wound healing, 
striae, telogen effluvium, hirsutism, 
fat atrophy 
Bone Osteoporosis, osteonecrosis, indirect 
hypocalcemia 
Gastrointestinal Peptic ulcer disease, bowel 
perforation, fatty liver, esophageal 
reflux, nausea, vomiting 
Lipid effects Hypertriglyceridemia, cushingoid 
habitus, menstrual irregularity 
Ocular Cataract, glaucoma, infection 
especially staphylococcus 
55 
Psychiatric Psychosis, agitation, personality 
changes,depression 
Muscular Myopathy 
Neurologic Pseudotumor cerebri, epidural 
lipomatosis, peripheral neuropathy 
Infections TB reactivation, oppurtunistics 
infections like deep fungal, etc. 
Pediatric  Growth impairement 
Pulse therapy  
 
Immediate flushing of face, hiccups, 
muscle weakness, asthenia,electrolyte 
shifts, cardiac dysarrythmias, 
seizures. 
The long term side effects are similar 
to daily steroid administration. 
Though its comparatively lower with 
pulse therapy 
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MATERIALS AND METHODS 
 It is a hospital - based prospective study. 
 The study was done with patients diagnosed as a case of Pemphigus vulgaris, 
attending the outpatient clinic in the Department Of Dermatology, 
Venereology, Leprosy, PSG IMS & R, Coimbatore. 
 The study was conducted over a period of one year after obtaining 
institutional ethics committee approval prior to the commencement of the 
study. 
 Informed and written consent was obtained from all the patients and from the 
histopathology department, PSG IMS & R, where the investigations were 
done. 
 The patients were then tested for direct immunofluorescence of oral mucosa 
and scalp hair. 
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INCLUSION CRITERIA 
 Patients diagnosed with Pemphigus Vulgaris by biopsy or/and DIF. 
 The patients had new or non-healing oral mucosal lesions. 
 
EXCLUSION CRITERIA 
 Patients with new or non healing skin lesions in the preceding 6 months. 
 Patients with other bullous disorders. 
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TABLE 3: METHODOLOGY FLOWCHART 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Informed and written consent was obtained 
26 patients with pemphigus vulgaris with only oral lesions 
were included in the study 
History and physical examination was done 
Data was recorded in the datasheet 
Oral mucosa sample was obtained from the patient‟s oral cavity. 
Hair sample was obtained in the same way as for a trichogram 
Oral mucosa and hair sample is transported immediately in the 
PBS medium to histopathology lab and subjected to direct 
immunofluorescence. 
The distal end of the hair shaft with the bulb and outer root 
sheath is cut to about 2 cm. 
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METHOD OF DIRECT IMMUNOFLUORESCENCE OF ORAL MUCOSA 
1. A punch Biopsy specimen from the Oral mucosa is received in the PBS 
medium. 
2. Specimen is then snap frozen in the cryostat. 
3. 5 frozen sections of 5μm thickness each is cut using a cryotome and placed 
on the slide. 
4. Fan dry the section for 10 minutes. 
5. The section is then washed in PBS at 7.4 pH for 10 minutes. 
6. Fan dry the section for 10 minutes. 
7. Each of the slide is then incubated in room temperature for 1 hour with one 
of the following FITC-labeled antisera - IgG & Fibrinogen each diluted 
1:200 in PBS & IgA, IgM, C3 each Diluted 1:100 in PBS (The PBS used in 
the above steps contains Propidium iodide which is a Counter-stain ). 
8. Wash the slides 3 times with PBS for 10 minutes each. 
9. Fan dry the sections 
10. Mount in buffered glycerol 
11. Examine under fluorescent microscope. 
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METHOD FOR DIRECT IMMUNOFLUORESCENCE OF HAIR 
1. The hair sample is received in PBS medium to the histopathology lab. 
2. Hair sample is placed over a Glass slide 
3. Washed three times with PBS medium for 10 minutes each 
4. Then the specimen is fan dried. 
5. Each of the slide is then incubated in room temperature for 1 hour with one 
of the following FITC-labeled antisera - IgG & Fibrinogen each diluted 
1:200 in PBS & IgA, IgM, C3 each Diluted 1:100 in PBS (The PBS used in 
the above step contains Propidium iodide which is a Counter-stain) 
6. Wash the slides 3 times with PBS for 10 minutes each 
7. Fan dry the sections 
8. Mount in buffered glycerol 
9. Examine under fluorescent microscope. 
 
Based on the presence or absence of immunofluorescence deposits in the 
specimen, the results were interpreted as positive or negative. 
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Statistical Analysis 
The data collected from the patients is tabulated using Microsoft Excel. The data 
has been reported in the tables as Percentages. The data was analyzed using Chi-
square test and Fisher‟s exact test. Chi-square test has been used for categorical 
variables and Fishers exact test is applied for 2*2 way table. Statistical analysis for 
the data collected was done using SPSS (Statistical Package for Social Sciences) 
with the version of 16.0. The p value was tested at 5% level of significance. 
 Sensitivity is the ability of a test to correctly classify an individual as 
′diseased′. 
 Specificity is the ability of a test to correctly classify an individual 
as „disease- free‟. 
 Positive predictive value is the probability that subjects with a positive 
screening test truly have the disease. 
 Negative predictive value is the probability that subjects with a negative 
screening test truly don't have the disease. 
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RESULTS 
TABLE 4: PATIENTS CHARACTERISTICS 
Total No. of patients (n) 26 
Age (years) Mean±SD 43 ± 13.87 
Sex - female:male 21 : 5 
Phenotype of Mucosal disease (n) 26 
History of scalp involvement  0 
Duration of Disease (months) 32 ±  21.16 
DIF positive with either substrate 13 
No. of positive hair DIF 19 
No of positive Oral Mucosa DIF 15 
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AGE DISTRIBUTION 
 
Fig 7- No. of patients in the various age groups 
 
 The age of patients in our study ranged from 17-66 years with a mean age of 
43.69 years. 
 Majority (30.8%) of the patients in our study were in the age group of 41-50 
years. 
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TABLE 5: GENDER DISTRIBUTION  
 
 
 
 
 
 
 
Fig 8- Pie chart showing gender ratio 
 Our study showed a female preponderance with a male-female ratio of 1:4.2 
 
5
21
Male
Female
Gender  Frequency Percent 
Male 5 19.2 
Female 21 80.8 
Total 26 100.0 
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DURATION OF THE DISEASE 
 
Fig 9- Duration of the disease 
 
 Mean duration of the disease in the patients taken up for the study was 32.61 
months. 
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TABLE 6: ORAL MUCOSA DIF FINDINGS 
 Frequency Percent 
Positive 15 57.7 
Negative 11 42.3 
Total 26 100.0 
 
 
Fig10-DIF findings of oral mucosa 
 
 15 out of the 26 patients showed DIF positivity of the oral mucosa. 
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TABLE 7: SCALP HAIR DIF FINDINGS 
 Frequency Percent 
Positive 19 73.1 
Negative 7 26.9 
Total 26 100.0 
 
 
 
Fig 11- DIF findings of scalp hair 
 
 19 out of the 26 patients showed DIF positivity in plucked scalp hair. 
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Oral Mucosa DIF results in different age groups 
 
Fig 12- DIF results of Oral mucosa in various age groups 
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Scalp Hair DIF results in different age groups 
 
Fig 13- DIF results of Scalp hair in various age groups 
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Hair DIF Results with respect to Gender 
 
Fig 14- DIF results of Scalp hair in male and female 
 
 Scalp Hair DIF positivity was seen in 16 out of 21 females and 3 out of 5 
male patients. 
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TABLE 8: FREQUENCY OF HAIR AND ORAL MUCOSA DIF 
Hair DIF 
Oral mucosa DIF 
Total P value Sensitivity Specificity Predictive  value 
Positive Negative 
Positive 
No. 13 6 19 
0.078 86.7 45.4 
Positive predictive 
value 68.4% % 68.4% 31.6% 100.0% 
Negative 
No. 2 5 7 
Negative predictive 
value  71.4% 
% 28.6% 71.4% 100.0% 
Total 
No. 15 11 26 
% 57.7% 42.3% 100.0% 
 
 With a „p value ‟ of 0.078 , there is no statistically significant difference between skin and hair DIF 
 Hair DIF showed a positive predictive value of 68.4% and negative predictive value of 71.4% 
 The sensitivity of Hair DIF was 86.7% while the specificity was 45.4%. 
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TABLE 9: CORRELATIONS 
Correlations Oral mucosa DIF Hair DIF 
Oral mucosa DIF Pearson Correlation 1 .358 
Sig. (2-tailed)  .073 
N 26 26 
Hair DIF Pearson Correlation .358 1 
Sig. (2-tailed) .073  
N 26 26 
 
 With the significant value of 0.073, there exists no correlation among Oral 
mucosa DIF and Hair DIF. 
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DISCUSSION 
Pemphigus is a chronic autoimmune bullous disorder characterized by 
autoantibodies against desmogleins 3 and / or 1.
1 
In about 70–90% of the cases, the first sign of the disease appears on the oral 
mucosa. Lesions may occur anywhere on the oral mucosa, but the buccal mucosa is 
the most commonly affected site followed by involvement of the palatal, lingual 
and labial mucosa. 125 
The oral cavity may be the only site of involvement for a year or so, and this 
may lead to delayed diagnosis and inappropriate treatment. If oral pemphigus 
vulgaris can be recognized in its early stages, treatment may be initiated to prevent 
the progression of the disease to skin involvement. Diagnostic delays of greater than 
6 months are common in patients with oral pemphigus vulgaris. 126 
The gold standard in the diagnosis of Pemphigus vulgaris is the 
demonstration of IgG and /or C3 by DIF in skin or oral mucosa and is also used to 
detect remission. 
Among the other modalities of confirmation available like antidesmoglein ELISA 
titres and indirect Immunofluorescence, DIF is preferred as anti desmoglein ELISA 
titres are expensive and not available in all clinical centres. 
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Wilson et al. in 1991, demonstrated that the human hair follicle is rich in the 
target antigens of pemphigus.
98 As the outer root sheath (ORS) of the hair follicle is 
structurally analogous to epidermal keratinocytes, pemphigus antigens are 
distributed throughout the ORS and in the dermal bulb matrix cells. 
Schaerer L, Trüeb RM in 2003, first reported the positive DIF findings in the 
Outer root sheath of plucked hair in 100% of their patients and hence, suggested 
that hair DIF could be a suitable and non-invasive alternative to skin DIF.
3 
Similarly a study of 50 patients with active pemphigus by Kumaresan, Rai R, 
et al in 2010, also demonstrated 100% positivity of hair DIF.
6 
Another study done by Daneshpazhooh et al in 2010 showed 81.8% of the 
cases showing Hair DIF positivity.
127 
Rao R et al in 2012, conducted a study to assess the role of hair DIF in 
monitoring the disease activity in pemphigus, they suggested that, in patients in 
clinical remission, DIF of hair could be an ideal substrate for assessment of 
immunological remission as it is simple and non- invasive.
128 
Another study done by Rai et al recommended that DIF of hair can be used 
as an additional procedure for the assessment of immunological remission in 
patients with pemphigus vulgaris.
129 
However, till date, there are only limited studies available, comparing the 
role of hair DIF in pemphigus patients with only mucosal lesions. 
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With this background we conducted a study in our department with 26 
patients with Pemphigus Vulgaris, who had only oral mucosal lesions on 
presentation and no skin lesions. None of the patients had previous history of scalp 
involvement. 
 Majority (30.8%) of the patients in our study were in the age group of 41-50 
years, However, western studies have reported the common age of onset as 
50-60 years.
22 
 
 Our study showed a female preponderance with male - female ratio of     1: 
4.2, which was similar to the gender ratio seen in a study done by Kanwar et 
al in North India and Mascarenhas MF et al in Goa.
130 
To our knowledge, 
there is only one study done by Daneshpazhooh et al done in Iran,which has 
compared DIF of oral mucosa to Scalp hair DIF.
5 
 
 In their study the hair sample was immediately frozen and sectioned while in 
our study the hair samples were directly mounted onto the slide for DIF 
without sectioning.
 
 
 The sensitivity of Hair DIF in our study was 86.7% which was similar to the 
sensitivity of Hair DIF in their study which was was 90.9%.
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Our study showed a positive predictive value of 68.4%.The positive 
predictive value refers to the probability that the patients with positive results, truly 
have the disease. 
In our study, among the 26 patients who had oral lesions, DIF positivity was 
seen in both the substrate in 13 patients (50%).  
6 patients (23%) had Hair DIF positivity while oral mucosa being negative 
and this is of significance as it showed that hair DIF can be positive despite DIF 
findings not being demonstrable in the oral mucosa. This can be explained by the 
findings in other studies as well were the sensitivity of Oral DIF may not reach 
100% and false negative results may occur.
5 
5 patients (19%) had DIF negativity of both substrates and this was 
important as it showed that the findings correlated in these patients as well.  
Hence, The findings of hair and oral mucosa DIF correlated with each other 
in 18 patients. 
The p value was tested at 5% level of significance and there was no 
statistically significant difference between oral mucosa and hair DIF with the „p 
value‟ of 0.078. 
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Even though skin or mucosa is considered as the ideal substrate for DIF 
which is the gold standard for diagnosis of Pemphigus patients, we would like to 
highlight the fact that 6 patients in our study had positive hair DIF even though oral 
DIF was negative. Had the clinician relied only on the oral DIF finding, the 
diagnosis would not be confirmed and hence treatment delayed as well. 
Pemphigus patients with oral lesions present with painful erosions and often 
secondary candidal infection as well, which causes pain and difficulty in even 
opening of the mouth. This poses a problem to the clinician as well as the patient to 
obtain the oral mucosa sample for DIF.  
Replacing this method with a much easier and non-invasive technique of plucking 
scalp hair is advantageous to both clinician as well as the patient. 
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CONCLUSION 
Our study was done to assess the role of hair DIF in the diagnosis of 
Pemphigus in patients with only oral lesions. The sensitivity of Hair DIF was high 
enough and comparable with other studies done which recommend DIF of oral 
mucosa as the gold standard for diagnosis of Pemphigus. 
The positivity of Hair DIF in the event of oral mucosa DIF being negative 
cannot be disregarded as well. 
Hence we suggest that plucked scalp hair can be used as a substrate for DIF 
in cases with oral Pemphigus, which is a simple, non invasive & cost effective 
procedure. 
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LIMITATIONS OF THE STUDY 
 
 Although the study has reached its aim, the unavoidable limitation was that 
the study was conducted on a small size of patients, because of the time limit. 
 
 Therefore we suggest that similar studies with much larger sample sizes are 
required before DIF of plucked hair can replace DIF of oral mucosa as a diagnostic 
tool. 
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CLINICAL PHOTOGRAPHS 
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PROFOMA 
 
Name:                                                   Gender: 
Age:                                                      Occupation:  
 
Address and telephone number:  
 
Complaints with duration of illness: 
 
 Type of Pemphigus: 
Sites of involvement:  
                            
History of scalp involvement:  
 
Current treatment: 
 
Duration of treatment: 
  
 
  
PSG Institute of Medical Science and Research, Coimbatore 
Institutional Human Ethics Committee 
INFORMED CONSENT FORMAT FOR RESEARCH PROJECTS 
 
(strike off items that are not applicable) 
 
 
I Dr. Ryan Raju,  am  carrying out a study on the topic: COMPARISON OF DIF OF ORAL MUCOSA AND 
PLUCKED HAIR IN PATIENTS WITH PEMPHIGUS. 
 
as part of my research project being carried out under the aegis of the Department of Dermatology   
 
My / our research guide is: Dr. Reena Rai 
 
The justification for this study is: Obtaining a sample for Direct Immunofluorescence (oral) biopsy imposes an 
invasive and unpleasant procedure to the patient. Hence finding a less invasive technique for collecting a 
suitable substrate would be of much help.  
 
 
The objectives of this study are:  
 
Primary Objective: Comparison of DIF of oral mucosa and plucked hair in patients with pemphigus. 
 
 
Sample size: 20 patients. 
 
Study volunteers / participants are (specify population group & age group): above 18 years of age.  
 
Location:Patients presenting to the dermatology OPD at PSGIMS & R , Coimbatore.  
 
We request you to kindly cooperate with us in this study. We propose collect background information and other 
relevant details related to this study. We will be carrying out:  
 
Initial interview (specify approximate duration) 15 minutes.  
 
Data collected will be stored for a period of 10 years. We will / will not use the data as part of another study. 
  
Benefits from this study: Based on the results of this study , to perfom only hair DIF & to avoid invasive 
oral biopsy procedure in patients with pemphigus. 
 
 
 
Risks involved by participating in this study: Infection, bleeding, scarring or pigmentation at the site of biopsy 
Risk of allergic reaction to the local anaesthetic. 
 
 
How the results will be used: Based on these results DIF of hair alone can be done as it is non invasive and 
simple procedure. And oral mucosa biopsy which is an invasive procedure can be avoided. 
 
 
If you are uncomfortable in answering any of our questions during the course of the interview / biological sample 
collection, you have the right to withdraw from the interview / study at anytime. You have the freedom to 
withdraw from the study at any point of time. Kindly be assured that your refusal to participate or withdrawal at 
any stage, if you so decide, will not result in any form of compromise or discrimination in the services offered nor 
would it attract any penalty. You will continue to have access to the regular services offered to a patient. You will 
NOT be paid any remuneration for the time you spend with us for this interview / study. The information 
provided by you will be kept in strict confidence. Under no circumstances shall we reveal the identity of the 
respondent or their families to anyone. The information that we collect shall be used for approved research 
purposes only. You will be informed about any significant new findings - including adverse events, if any, – 
whether directly related to you or to other participants of this study, developed during the course of this research 
which may relate to your willingness to continue participation. 
 
Consent: The above information regarding the study, has been read by me/ read to me, and has been 
explained to me by the investigator/s. Having understood the same, I hereby give my consent to them to 
interview me. I am affixing my signature / left thumb impression to indicate my consent and willingness to 
participate in this study (i.e., willingly abide by the project requirements).  
 
Signature / Left thumb impression of the Study Volunteer / Legal Representative:  
 
 
Signature of the Interviewer with date:      Witness: 
 
Contact number of PI: 9995051845 
 
Contact number of Ethics Committee Office:  During Office hours: 0422 2570170 Extn.: 5818  
                                                                        After Office hours: 9865561463 
 
 
 
 
 
 
 
 
  
 
  
Xg;gjy; gotk; 
 
njjp          
 
uad; uh$;  Mfpa ehd;  PSG kUj;Jtf;fy;Y}hpapd; njhy; ghy;tpid kw;Wk; 
bjhGneha;  Jiwapd; fPH;  “vjph; mqtpdhy; cz;lhff;Toa  bfhg;gs nehapd; 
bray;ghL  jd;ikia fz;lwpa/  o.I.vg; vd;Dk; kUj;Jt ghpnrhjidapy; jiyKo 
kw;Wk; tha; $t;tpy; ,Ue;J ghpnrhjpg;gjpy; vJ rpwe;jJ vd;gij fz;lwpa[k; Ma;t[ ” 
vd;w  jiyg;gpy; Ma;t[ nkw;bfhs;s cs;nsd; 
 
vd; Ma;t[ tHpfhl;o :   kU. hPdhuha; 
Ma;t[ nkw;bfhs;tjw;fhd mog;gil 
 
njhypy; bfhg;gs neha; cz;lhtjw;F ekJ clypy; cs;s vjph;g;g[ rf;jp njhypy; 
,aw;ifahf cs;s  gir  nghd;w xU bghUSf;F vjph; mqit gy;ntW 
fhuz';fshy; cUthf;FfpwJ.  ,e;j gir nghd;w bghUspy; bray;jpwd; Fiwa[k; 
bghGJ xU bry; kw;bwhU bry;ypypUe;J gphpfpwJ.  ,Jnt bfhg;gs';fshf 
btspg;gLfpwJ.  ,e;j vjph; mqf;fis Fiwg;gjw;F kUe;Jfs; tH';fg;gLk;.  Mdhy; 
vd;W kUe;ij epWj;jntz;Lk; vd;gij jPh;khdpf;f njhy; kw;Wk; Koapy; cs;s 
nth;fspy; vjph;g;g[ mq cs;sjh vd;gij ghpnrhjpf;f 6 khj';fSf;F xU Kiw 
njhy; kw;Wk; Koia  o.I. vg;. vd;w ghpnrhjidia nkw; bfhs;s ntz;Lk;.  ,jid 
itj;J nehapd; bray;ghL  jd;ikia fz;lwpa ,aYk;.   
 
Ma;tpd; nehf;fk;  
 nkw;Twpa o.I.vg; vd;Dk; kUj;Jt ghpnrhjidapy; jiyKo kw;Wk; tha; 
$t;tpy; ,Ue;J ghpnrhjpg;gjpy; vJ rpwe;jJ vd;gij fz;lwpa[k; Ma;t[. 
 
Ma;tpy; g';F bgWk; egh;fspd; vz;zpf;if  :   20 egh;fs; 
Ma;tpy; g';F bgWnthh; kw;Wk; taJ : 18 tajpw;F nky;  cs;s Mz;fSk; 
bgz;fSk;. 
 
 
Ma;t[ nkw;bfhs;Sk; ,lk; :   gp.v!;.$p kUj;Jtkid/  
njhy; ghy;tpid kw;Wk; bjhGneha; Jiw 
 
eP';fs; jat[ bra;J v';fspd; Ma;t[f;F xj;JiHf;f ntz;Lk; vd;W gzpt[ld; 
nfl;Lf; bfhs;fpnwd;. eh';fs; rpy jfty;fis ,e;j Ma;tpw;fhf nrfhpf;f 
cs;nshk;. 
 
Ma;t[ bra;ag;gLk; Kiw  
 
Kjd;ik neh;fhzy;  :   15 epkpl';fs; 
 
,e;j Ma;tpy; fpilf;Fk; jfty;fs;  10 tUl';fs; ghJfhf;fg;gLk;.  ,it ntW ve;j 
Ma;tpw;F gad;gLj;jg;glkhl;lhJ. 
         
Ma;tpy; g';F bgWtjhy; Vw;gLk; gyd;fs; : 
 
 bghJthf DIF ghpnrhjidf;F rij vLg;gJ nehahspf;F mr;RWj;jiy 
Vw;gLj;Jk;.  Mifahy; ,e;j Ma;tpd; \yk; Koia itj;J kpf  vspikahd 
Kiwapy; ghpnrhjid bra;agLk;. 
 
Ma;tpdhy; Vw;gLk; mbrsfhpa';fs; / gf;f tpist[fs;; : 
 
 nehahspfSf;F rij vLf;Fk;bghGJ rpyUf;F cjpug;nghf;F Vw;glyhk;.  
mJt[k; xU ijay; \yk; (njitg;gl;lhy;) rhp bra;ayhk;.  fpUkpfs; bjhw;Wk; mghak; 
kpft[k; Fiwe;j mstpy; cs;sJ.  v';fsJ fpUkp ehrp bray; \yk; ,Jt[k; 
jtph;f;fg;gLk;.  rij vLj;j gFjpapy; rpyUf;F fhak; Vw;glyhk;. rpyUf;F 
kuj;Jg;nghFk; kUe;jpdhy; myh;$p Vw;glyhk;. 
  
Ma;tpd; Kot[fs; ve;j Kiwapy; gad;gLj;jg;gLk;  
 ve;j epiyapYk; c';fisg; gw;wpa jfty;fs; ahUf;Fk; bjhptpf;fg;gl 
khl;lhJ.  ,it ,ufrpakhf itf;fg;gLk;. 
,e;j Ma;tpy; g';nfw;f xg;g[f; bfhs;Stjhy; ve;jtpjkhd gyDk; c';fSf;F 
fpilf;fhJ.   
ve;j neuj;jpy; ntz;LkhdhYk; Ma;tpypUe;J tpyfpf; bfhs;Sk; chpik 
c';fSf;F cz;L. 
Ma;tpypUe;J tpyfpf; bfhs;tjhy; c';fSf;F mspf;fg;gLk; rpfpr;irapy; ve;j 
tpj khw;wKk; ,Uf;fhJ. 
,e;j Muha;r;rpf;fhf c';fsplk; rpy nfs;tpfs; nfl;fg;gLk; / rpy ,uj;j 
khjphpfs; my;yJ jpR khjphpfs; vLf;fg;gLk;. 
nkYk; ,e;j Ma;tpy; g';F bfhs;tJ c';fs; brhe;j tpUg;gk;.  ,jpy; ve;j  
tpjf; fl;lhaKk; ,y;iy.   
eP';fs; tpUg;gg;gl;lhy; ,e;j Ma;tpd; Kot[fs; c';fSf;Fj; bjhpag; 
gLj;jg;gLk;. 
 
Ma;t[f;Fl;gLgthpd; xg;g[jy; 
,e;j Ma;itg; gw;wpa nkw;Twpa jfty;fis ehd; goj;J mwpe;J bfhz;nld; / 
Ma;thsh; gof;f nfl;Lf; nfl;Lj; bjhpe;J bfhz;nld;.  Ma;tpidg; gw;wp ed;whfg; 
g[hpe;J bfhz;L ,e;j Ma;tpy; g';F bgw xg;g[f; bfhs;fpnwd;.  ,e;j Ma;tpy; 
g';nfw;gjw;fhd vdJ xg;g[jiy fPnH ifbahg;gkpl;L / if nuif gjpj;J ehd; 
bjhptpj;Jf; bfhs;fpnwd;. 
 
g';FbgWgthpd; bgah;/ Kfthp  : 
g';FbgWgthpd; ifbahg;gk; / ifnuif / rl;lg{h;t  gpujpepjpapd; ifbahg;gk; : 
njjp  : 
 
Ma;thshpd; ifbahg;gk; : 
 
njjp : 
 
 kdpj bewpKiwf; FG mYtyfj;jpd; bjhiyngrp vz;. 0422-2570170  Extn. 5818 
 
 
 
 
ABBREVIATIONS 
PV   - Pemphigus Vulgaris 
PF   -  Pemphigus Foliaceous  
Dsg  -  Desmogleins  
ORS   -  Outer Root Sheath 
IRS   -  Inner root sheath 
DIF   -  Direct Immunofluorescence 
IIF   -  Indirect Immunofluorescence 
IgG  -  Immunoglobulin G 
FITC   -  Fluorescent isothiocyanate 
CS   - Corticosteroids 
DCP   - Dexamethasone Cyclophosphamide pulse therapy 
TPMT  -  Thio-purine Methytransferase 
DVT   -  Deep vein thrombosis 
BSA   -  Body surface area 
 H&E   - Hematoxylin and Eosin 
IVIg   -  Intravenous immunoglobulin  
SLE   -  Systemic Lupus Erythematosus 
EBV   -  Ebstein Barr Virus  
HHV  -  Human Herpes Virus 
ELISA -  Enzyme-Linked Immunosorbent Assay 
HIV  -  Human Immunodeficiency Virus 
